Skip to the beginning of the images gallery

Add to Wish List

Tislelizumab Biosimilar - Research Grade

Name: Tislelizumab Biosimilar - Research Grade
SKU: ICH5004
Price: 315 USD
Availability: InStock

In stock

Only %1 left

SKU

ICH5004

Add to Compare

Be the first to review this product

$315.00 - $19,890.00

Tislelizumab Biosimilar - Research Grade

Endotoxin

<1 EU/mg Determined by LAL gel clotting assay

Purity

>95% by SDS-PAGE and HPLC

Species Reactivity

Human

Target

PD-1

Concentration

>1mg/ml

Isotype

Human IgG4

Host

Humanized

Antibodies Against The Same Target

Sequence

https://www.imgt.org/mAb-DB/

Buffer

ICH3002

Uniprot

Q15116

Shipping Conditions

Blue ice

Background

This product is an unconjugated, non-therapeutic recombinant analog of the anti-PD-1 antibody tislelizumab, produced for research use only. It is built around human PD-1 (PDCD1, UniProt Q15116) as a fully recombinant human IgG4 protein and is not the clinical drug, nor is it intended for human or veterinary use. As a research-grade biosimilar it is useful wherever a well-characterized, reproducible anti-PD-1 binder is needed: as a positive control or reference standard in binding, blocking, and neutralization assays; as a benchmarking tool for developing or validating new checkpoint-directed antibodies, bispecifics, or ADCs; and in cell-based in-vitro systems probing T-cell activation and PD-1/PD-L1 axis biology. It is supplied unconjugated to allow downstream labeling or format conversion. Material is offered at low endotoxin (research grade <1 EU/mg; ultra-low <0.5 EU/mg) and in bulk milligram-to-gram quantities to support screening campaigns, assay development, and preclinical work requiring consistent lot-to-lot performance at scale. PD-1 (programmed cell death protein 1, gene PDCD1; UniProt Q15116) is a type I transmembrane immune-checkpoint receptor of the CD28/immunoglobulin superfamily, expressed on activated T cells, B cells, NK cells, and myeloid subsets. Its cytoplasmic tail carries ITIM and ITSM motifs that, upon engagement of its ligands PD-L1 (CD274) and PD-L2 (PDCD1LG2), recruit the phosphatase SHP-2 to dephosphorylate TCR/CD28 signaling components. This delivers an inhibitory signal that attenuates T-cell proliferation, cytokine production, and effector function, maintaining peripheral tolerance and limiting immunopathology. Tumors and chronically infected tissues co-opt this pathway to drive T-cell exhaustion, making PD-1 a central target for checkpoint blockade. Antibodies that block the PD-1/PD-L1 interaction restore effector responses, the mechanistic basis for anti-PD-1 immunotherapy.

Other Names

Programmed cell death protein 1, Pdcd1, CD279

Specificity

Detects human PD-1. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Tislelizumab.

Purification Method

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Formulation

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Storage

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Applications

Functional Assays

Application Notes

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Write Your Own Review

You're reviewing:Tislelizumab Biosimilar - Research Grade

Your Rating

Rating